Factor XII inhibitors for the treatment of neurological inflammatory disorders

US9957329B2 · kind B2 · utility

Assignees

• CSL Behring AG · DE
• CSL LIMITED · AU
• Julius-Maximilians-Universitat Wurzburg · DE
• WESTFÄLISCHE WILHELMS-UNIVERSITÄT MÜNSTER · DE

Inventors

• Sven Meuth · Munster, DE
• Kerstin Goebel · Mindelheim, DE
• Christoph Kleinschnitz · Heiligenhaus, DE
• Brent McKenzie · San Mateo, US
• Marc Nolte · Marburg, DE

Key dates

• Filing date: Jan 31, 2013
• Grant date: May 1, 2018
• Expiry date: Jan 31, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This application relates to neurological inflammatory diseases, such as multiple sclerosis, and to methods of administering a Factor XII inhibitor to prevent, treat, or otherwise ameliorate the effects of a neurological inflammatory disease, such as multiple sclerosis. Agents and pharmaceutical compositions comprising agents which inhibit the activity of FXII are also provided.